argenx Announces Leadership Transition as Karen Massey Set to Replace Tim Van Hauwermeiren as CEO
Key Insights
argenx announced that current COO Karen Massey will transition to CEO while co-founder Tim Van Hauwermeiren moves to Chairman of the Board of Directors.
The leadership changes are subject to shareholder approval at the Annual General Meeting on May 6, 2026, allowing for a comprehensive transition period.
Van Hauwermeiren praised Massey's exceptional impact over three years, including accelerating VYVGART's launch and building the company's commercial engine.
argenx SE, a global immunology company focused on severe autoimmune diseases (search), announced a significant leadership transition that will see current Chief Operating Officer Karen Massey become Chief Executive Officer while co-founder Tim Van Hauwermeiren transitions to Chairman of the Board of Directors. The changes are subject to shareholder approval at the Annual General Meeting scheduled for May 6, 2026.
Leadership Evolution for Next Growth Phase
The transition represents what the company describes as a natural evolution as argenx prepares for its next phase of growth. Van Hauwermeiren will succeed Peter Verhaeghe, who is retiring from the Board of Directors after serving the company since 2008.
"This leadership evolution comes at the right time and represents a natural step as we prepare for the next phase of growth at argenx - a long-term future that remains bold, patient-focused, and built to last," said Peter Verhaeghe, Chairman of the Board of Directors.
Massey's Track Record and Future Vision
Van Hauwermeiren highlighted Massey's exceptional performance since joining argenx three years ago, specifically noting her role in accelerating VYVGART's launch and building what he described as a "future-proof commercial engine." VYVGART represents the company's first approved neonatal Fc receptor (FcRn (search)) blocker, which argenx is evaluating for multiple serious autoimmune diseases (search).
"Karen has delivered exceptional impact since joining argenx three years ago - accelerating VYVGART's launch, building a future-proof commercial engine, being a leading ambassador of our culture, and connecting to and inspiring our teams," Van Hauwermeiren stated.
Strategic Focus on Vision 2030
Massey emphasized her commitment to executing the company's Vision 2030 strategy while maintaining what she called the "unique argenx DNA." The incoming CEO highlighted the company's foundation built on scientific strength, entrepreneurial culture, and team accountability to transform patient lives.
"My commitment is to elevate the unique argenx DNA as we execute on Vision 2030 and beyond and to ensure we are making the most of this bold opportunity to build the biotech company of the future," Massey said.
Van Hauwermeiren's Continued Role
As Chairman, Van Hauwermeiren plans to serve as a strategic advisor to Massey and the leadership team on long-term strategy while maintaining engagement with the external innovation ecosystem. The co-founder expressed that this transition aligns with his long-term ambition to build a strong, independent biotech company.
Company Background and Pipeline
argenx operates as a global immunology company committed to improving lives of people with severe autoimmune diseases (search). The company partners with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into novel antibody-based medicines. Beyond VYVGART, argenx is advancing several earlier-stage experimental medicines within its therapeutic franchises.
The leadership transition comes as the company continues to evaluate the broad potential of its FcRn (search) blocker technology across multiple autoimmune indications while building its portfolio of antibody-based therapeutics.